<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:mp ids='MP_0001845'>Inflammation</z:mp> is important for lung <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Use of <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) has been shown to improve <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival </plain></SENT>
<SENT sid="2" pm="."><plain>However, few studies have examined the association in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The VITamins And Lifestyle (VITAL) cohort includes Washington State residents, aged 50 to 76 years, who completed a baseline questionnaire between 2000 and 2002 </plain></SENT>
<SENT sid="4" pm="."><plain>Participants responded on the frequency and duration of use of individual <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> in the previous 10 years </plain></SENT>
<SENT sid="5" pm="."><plain>Subjects of this study were 785 members of the cohort, who were identified with incident <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> from baseline through 2007 through linkage to a population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry </plain></SENT>
<SENT sid="6" pm="."><plain>Participants were followed for <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> through linkage to state records of <z:hpo ids='HP_0011420'>death</z:hpo> through 2009 </plain></SENT>
<SENT sid="7" pm="."><plain>Adjusted proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Five hundred and twenty-two participants (66%) died from <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Relative to nonuse, high (��� 4 days/week and ≥ 4 years) prediagnostic use of regular-strength or low-dose aspirin (HR 0.99, 95% CI: 0.74-1.33 and HR 0.89, 95% CI: 0.67-1.17, respectively) or total nonaspirin <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> (HR 1.20, 95% CI: 0.79-1.83) did not reduce <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>However, high use of <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> was associated with a 62% increased risk of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> (HR 1.62, 95% CI: 1.01-2.58) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Long-term, prediagnostic <z:chebi fb="1" ids="35475">NSAID</z:chebi> use does not improve <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> survival overall </plain></SENT>
<SENT sid="12" pm="."><plain>Use of <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> may reduce survival from <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Our results underscore the need for further study of the mechanisms of action for individual <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> with regard to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survival </plain></SENT>
</text></document>